These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

495 related articles for article (PubMed ID: 28429246)

  • 1. Comparison of Efficacy and Safety of Caspofungin Versus Micafungin in Pediatric Allogeneic Stem Cell Transplant Recipients: A Retrospective Analysis.
    Maximova N; Schillani G; Simeone R; Maestro A; Zanon D
    Adv Ther; 2017 May; 34(5):1184-1199. PubMed ID: 28429246
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized trial of micafungin versus fluconazole as prophylaxis against invasive fungal infections in hematopoietic stem cell transplant recipients.
    Park S; Kim K; Jang JH; Kim SJ; Kim WS; Chung DR; Kang CI; Peck KR; Jung CW
    J Infect; 2016 Nov; 73(5):496-505. PubMed ID: 27394404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antifungal prophylaxis with micafungin in patients treated for childhood cancer.
    Kusuki S; Hashii Y; Yoshida H; Takizawa S; Sato E; Tokimasa S; Ohta H; Ozono K
    Pediatr Blood Cancer; 2009 Oct; 53(4):605-9. PubMed ID: 19533659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of caspofungin or micafungin as empiric antifungal therapy in adult patients with persistent febrile neutropenia: a retrospective, observational, sequential cohort analysis.
    Kubiak DW; Bryar JM; McDonnell AM; Delgado-Flores JO; Mui E; Baden LR; Marty FM
    Clin Ther; 2010 Apr; 32(4):637-48. PubMed ID: 20435233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of Invasive Fungal Infections in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: The Turin Experience.
    Busca A; Cinatti N; Gill J; Passera R; Dellacasa CM; Giaccone L; Dogliotti I; Manetta S; Corcione S; De Rosa FG
    Front Cell Infect Microbiol; 2021; 11():805514. PubMed ID: 35071052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Micafungin as antifungal prophylaxis in recipients of allogeneic hematopoietic stem cell transplantation: results of different dosage levels in clinical practice.
    Langebrake C; Rohde H; Lellek H; Wolschke C; Kröger NM
    Clin Transplant; 2014 Mar; 28(3):286-91. PubMed ID: 24479680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of micafungin for prophylaxis of invasive fungal infections in patients undergoing haplo-identical hematopoietic SCT.
    El-Cheikh J; Venton G; Crocchiolo R; Fürst S; Faucher C; Granata A; Oudin C; Coso D; Bouabdallah R; Vey N; Duran S; Fougereau E; Berger P; Chabannon C; Blaise D
    Bone Marrow Transplant; 2013 Nov; 48(11):1472-7. PubMed ID: 23749104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Secondary antifungal prophylaxis in pediatric hematopoietic stem cell transplants.
    Azik FM; Tezer H; Ozkaya-Parlakay A; Aksu T; Bayram C; Fettah A; Tavil B; Tunç B
    J Pediatr Hematol Oncol; 2015 Jan; 37(1):e19-22. PubMed ID: 25522351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of micafungin for prophylaxis against invasive fungal infections in Japanese patients undergoing hematopoietic stem cell transplantation: Results of a post-marketing surveillance study.
    Kobayashi C; Hanadate T; Niwa T; Hirano Y; Yoshiyasu T; So M; Matsui K
    J Infect Chemother; 2015 Jun; 21(6):438-43. PubMed ID: 25749360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness analysis of antifungal prophylaxis in patients undergoing hematopoietic stem cell transplantation.
    Schonfeld W; Wang Cheng J; Tong KB; Seifeldin R
    Clin Ther; 2008 May; 30(5):964-73. PubMed ID: 18555943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of micafungin for the prophylaxis of invasive fungal infection during neutropenia in children and adolescents undergoing allogeneic hematopoietic SCT.
    Park HJ; Park M; Han M; Nam BH; Koh KN; Im HJ; Lee JW; Chung NG; Cho B; Kim HK; Yoo KH; Koo HH; Kang HJ; Shin HY; Ahn HS; Lim YT; Kook H; Lyu CJ; Hah JO; Park JE; Lim YJ; Seo JJ
    Bone Marrow Transplant; 2014 Sep; 49(9):1212-6. PubMed ID: 25000455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multicenter, randomized, open-label study comparing the efficacy and safety of micafungin versus itraconazole for prophylaxis of invasive fungal infections in patients undergoing hematopoietic stem cell transplant.
    Huang X; Chen H; Han M; Zou P; Wu D; Lai Y; Huang H; Chen X; Liu T; Zhu H; Wang J; Hu J
    Biol Blood Marrow Transplant; 2012 Oct; 18(10):1509-16. PubMed ID: 22469884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness analysis of micafungin versus fluconazole for prophylaxis of invasive fungal infections in patients undergoing hematopoietic stem cell transplantation in Korea.
    Sohn HS; Lee TJ; Kim J; Kim D
    Clin Ther; 2009 May; 31(5):1105-15; discussion 1066-8. PubMed ID: 19539111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alternate-day micafungin antifungal prophylaxis in pediatric patients undergoing hematopoietic stem cell transplantation: a pharmacokinetic study.
    Mehta PA; Vinks AA; Filipovich A; Bleesing J; Jodele S; Jordan MB; Marsh R; Tarin R; Edwards S; Fearing D; Lawrence J; Davies SM
    Biol Blood Marrow Transplant; 2010 Oct; 16(10):1458-62. PubMed ID: 20546908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation.
    van Burik JA; Ratanatharathorn V; Stepan DE; Miller CB; Lipton JH; Vesole DH; Bunin N; Wall DA; Hiemenz JW; Satoi Y; Lee JM; Walsh TJ;
    Clin Infect Dis; 2004 Nov; 39(10):1407-16. PubMed ID: 15546073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Feasibility and effectiveness of posaconazole prophylaxis in combination with micafungin bridging for patients undergoing allogeneic stem cell transplantation: a 6-yr analysis from the cologne cohort for neutropenic patients.
    Vehreschild MJ; von Bergwelt-Baildon M; Tran L; Shimabukuro-Vornhagen A; Wisplinghoff H; Bangard C; Cornely OA; Vehreschild JJ
    Eur J Haematol; 2014 Nov; 93(5):400-6. PubMed ID: 24798021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Caspofungin as antifungal prophylaxis in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation: a retrospective analysis.
    Döring M; Hartmann U; Erbacher A; Lang P; Handgretinger R; Müller I
    BMC Infect Dis; 2012 Jul; 12():151. PubMed ID: 22747637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Caspofungin as primary antifungal prophylaxis in stem cell transplant recipients.
    Chou LS; Lewis RE; Ippoliti C; Champlin RE; Kontoyiannis DP
    Pharmacotherapy; 2007 Dec; 27(12):1644-50. PubMed ID: 18041885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequential systematic anti-mold prophylaxis with micafungin and voriconazole results in very low incidence of invasive mold infections in patients undergoing allogeneic hematopoietic stem cell transplantation.
    Rosillo C; Avila AM; Huang YT; Devlin S; Cho C; Montoro J; Maloy MA; Papanicolaou GA; Barba P; Perales MA
    Transpl Infect Dis; 2018 Aug; 20(4):e12897. PubMed ID: 29668073
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A cost and resource utilization analysis of micafungin bridging for hemato-oncological high-risk patients undergoing allogeneic stem cell transplantation.
    Heimann SM; Vehreschild MJ; Cornely OA; Franke B; von Bergwelt-Baildon M; Wisplinghoff H; Kron F; Scheid C; Vehreschild JJ
    Eur J Haematol; 2015 Jun; 94(6):526-31. PubMed ID: 25310918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.